Shares of Vertex Pharmaceuticals plunged more than 14% to $404.89 after it release disappointing top-line results from its recently completed Phase II, randomized, double-blind, placebo-controlled ...

A New York-based healthcare investment firm has announced that it has raised $1.86 billion in commitments for OrbiMed Royalty ...

Swedish biotech Hansa Biopharma on Friday released encouraging top-line results from three patients with Duchenne muscular ...

Germany’s BioNTech has reported revenues for the second quarter 2025 of 260.8 million euros ($302 million), more than double ...

Philadelphia, USA-based Medicus Pharma and Boston-based biotech Helix Nanotechnologies have entered into a non-binding ...

The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla (donanemab-azbt) continued to demonstrate ...

Chinese biotech Mabgeek Biotechnology has filed to go public in Hong Kong, seeking to raise funds to support development of ...

Chinese biotech TenNor Therapeutics has filed to list on the main board of the Hong Kong Stock Exchange, aiming to fund ...

Biosimilars, once met with skepticism, are now an undeniable force in the global pharmaceutical market. As several ...

New York-based Spine BioPharma on Friday revealed disappointing results with its growth factor beta (TGF-β) antagonist, SB-01 ...

Allogene Therapeutics, a US biotech developing allogeneic CAR T products for cancer and autoimmune disease, closed 12% lower ...